Opendata, web and dolomites

CareMin650 SIGNED

An unrivalled medical device for severe cancer treatment complications:exact & easy red-LED photobiomodulation for mucositis and dermatitis

Total Cost €


EC-Contrib. €






Project "CareMin650" data sheet

The following table provides information about the project.


Organization address
postcode: 69100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country France [FR]
 Total cost 3˙419˙936 €
 EC max contribution 2˙393˙955 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2019
 Duration (year-month-day) from 2019-05-01   to  2021-04-30


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    NEOMEDLIGHT FR (VILLEURBANNE) coordinator 2˙393˙955.00


 Project objective

Today the healthcare system is under great pressure due to the increasing incidence of cancer, which is also affected by ageing of the population. However, all efforts in the medical industry have concentrated on early diagnosis and treatment of cancer, so that this is becoming a chronic disease. The surfacing challenge from now on will be improving the quality of life of cancer patients. Mucositis and radiodermatitis are the most common and most debilitating side effects suffered by cancer patients but, so far, there is no approved preventive or curative treatment. In the last years, photobiomodulation has gained traction but the technology is still expensive, complex and inaccurate. CareMin650 is an innovative LED-based phototherapy device that will make photobiomodulation for the treatment of these conditions accurate, easy and inexpensive, thanks to its flexible fabric made of woven optic fibre. Neomedlight is proprietary of this core technology and knows a previous market success across Europe applying it to the niche market of jaundice treatment with Bilicocoon®. We now have validated the reliability of CareMin650 to deliver a fast, comfortable and painless treatment for patients; these are the added values to our central value proposition: a system for preventive and curative delivery of an accurate dose of red light. Moreover, this is a cost-effective solution to increase the quality of life and the survival of cancer patients: In the EU alone, CareMin650 will contribute to reduce the 200,000 cancer deaths and the €27.9 billion economic burden associated to mucositis and radiodermatitis. We have a huge untapped market ahead and now want to finalise CareMin650 development and achieve market preparedness. The SME Phase 2 project will allow NeoMedLight to put on the market a medical device that will boost the growth of the company, with an expected €20.8 million cumulative profit, a ROI of 5.08 and from 8 to 20 new job positions by 2025.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CAREMIN650" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CAREMIN650" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Colourganisms (2020)

Microbial production of custom-made, pure and sustainable anthocyanins

Read More  

AMBRPAY (2019)

Decentralized subscription payments with cryptocurrency

Read More  


Specialized Help from Be My Eyes – harnessing technology to connect companies directly with their blind and visually impaired users

Read More